Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.4050.4050
Abstract: Introduction: PI3Kδ inhibition has demonstrated significant efficacy in the treatment of lymphoid malignancies, leading to the approval of idelalisib as a single agent for follicular lymphoma and SLL and in combination with rituximab in CLL.… read more here.
Keywords: lymphoma; inhibitor; treatment; consultancy ... See more keywords
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.17869
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to… read more here.
Keywords: pi3k mtor; inhibitor; dual inhibitor; mtor dual ... See more keywords
Copanlisib: Novel PI3K Inhibitor for Treatment of Lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520620666200317105207
Abstract: Lymphoma refers to a specialized category of blood cancers which is characterized by lymph node enlargement, reduced body weight, prolonged tiredness and fever associated with sweats. Traditional treatment strategies involve chemotherapy, radiation therapy, targeted therapy,… read more here.
Keywords: lymphoma; treatment; copanlisib novel; novel pi3k ... See more keywords